Life Molecular Imaging’s [18F] PI-2620 Gains the US FDA’s Fast Track Designation for PET Imaging in Various Neurodegenerative Disorders
Shots:
- The US FDA has granted fast track designation to [18F] PI-2620 injection for imaging in neurodegenerative disorders such as Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD)
- [18F] PI-2620 is being assessed under the P-III clinical evaluation for detecting tau pathology in Alzheimer’s disease, with ongoing research in other neurodegenerative diseases by academic researchers & other drug development studies
- [18F] PI-2620 is a PET imaging agent developed under a partnership b/w AC Immune and LMI, with LMI securing exclusive rights for research, development & commercialization of Tau PET tracers generated within the discovery program
Ref: Life Molecular Imaging | Image: Life Molecular Imaging
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
